The sphingolipid-rich rafts of ALK+ lymphomas downregulate the Lyn-Cbp/PAG signalosome

European Journal of Haematology

Volumn 85, Issue 2, 2010, Pages 93-98

  Yerly, Stéphane ^a   Ding, Heidrun ^a   Tauzin, Sébastien ^a,d   Van Echten Deckert, Gerhild ^b   Borisch, Bettina ^c   Hoessli, Daniel C ^a,e  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

anaplastic lymphoma kinase + lymphomas; B non Hodgkin lymphomas; Cbp PAG adaptor; rafts; sphingolipids; Src family kinases

Indexed keywords

ADAPTOR PROTEIN; ANAPLASTIC LYMPHOMA KINASE; GLYCOSPHINGOLIPID; MEMBRANE LIPID; NUCLEOPHOSMIN; PHOSPHOPROTEIN; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; SPHINGOLIPID; TRANSCRIPTION FACTOR;

ARTICLE; CELL FRACTIONATION; CELL MEMBRANE; CELLULAR DISTRIBUTION; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME MECHANISM; HUMAN; HUMAN CELL; LIPID MEMBRANE; LIPID RAFT; LYMPHOMA; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAJI CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL MEMBRANE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MEMBRANE MICRODOMAINS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SRC-FAMILY KINASES;

EID: 77954725911     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01492.x     Document Type: Article

References (35)

1. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin disease associated Ki1-antigen in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic maligancies are derived from activated lymphoid cells. Blood 1985 66 : 848 858.
2. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008 8 : 11 23.
3. Pulford K, Morris S, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004 199 : 330 358.
4. Ait-Tahar K, Cerundolo V, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006 118 : 688 695.
5. Ait-Tahar K, Barnardo MC, Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007 67 : 1898 1901.
6. Borisch B, Yerly S, Cerato Ch, Schwaller J, Wacker P, Ozsahin AH, Brousse N, Hoessli DC. ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumor responses may cause hypocellular aspect of lymph node mimicking inflammatory lesions. Eur J Haematol 2003 71 : 243 249.
7. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010 115 : 3314 3319.
8. Crockett CK, Lin Z, Elenitoba-Johnson K, Lim MS. Identification of NPM-ALK interacting proteins by mass spectrometry. Oncogene 2004 23 : 2617 2629.
9. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T. Role of phosphatidylinositol 3-kinase-akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001 61 : 2194 2199.
10. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N, Wasik MA. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and STAT3 phosphorylation independently of Jak3. Lab Invest 2005 85 : 1544 1554.
11. Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001 61 : 6517 6523.
12. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/Null-cell lymphoma. J Immunol 2002 168 : 466 474.
13. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 2005 36 : 939 944.
14. Bischof D, Pulford K, Mason D, Morris S. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma- associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997 17 : 2312 2325.
15. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007 110 : 2259 2267.
16. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008 68 : 8899 8907.
17. Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, Payrastre B, Gaits-Iacovoni F. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 2007 27 : 2728 2736.
18. Tauzin S, Ding H, Khatib K, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 2008 111 : 2310 2320.
19. Brdicka T, Pavlistová D, Leo A, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase Csk and is involved in regulation of T cell activation. J Exp Med 2000 191 : 1591 1604.
20. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 2000 404 : 999 1003. (Pubitemid 30243594)
21. Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B, Hoessli DC. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003 63 : 534 540.
22. Arni S, Ilangumaran S, van Echten-Deckert G, Sandhoff K, Poincelet M, Briol A, Rungger-Brandle E, Hoessli DC. Differential regulation of Src-family protein tyrosine kinases in GPI domains of T lymphocyte plasma membranes. Biochem Biophys Res Commun 1996 225 : 801 807.
23. Ilangumaran S, Arni S, Chicheportiche Y, Briol A, Hoessli DC. Evaluation by dot-immunoassay of the differential distribution of cell surface and intracellular proteins in glycosylphosphatidylinositol-rich plasma membrane domains. Anal Biochem 1996 235 : 49 56.
24. Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J. Apoptosis Induced in Burkitt's Lymphoma Cells Via Gb3/CD77, a Glycolipid Antigen. Cancer Res 1993 53 : 5314 5319.
25. Wan W, Albom MS, Lu L, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006 107 : 1617 1623.
26. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kB activation in anaplastic large cell lymphoma. Cancer Cell 2004 5 : 353 364.
27. Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-ud-Din. Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform. Glycoconj J 2000 17 : 1 7.
28. Ilangumaran S, Arni S, van Echten-Deckert G, Borisch B, Hoessli DC. Microdomain-dependent regulation of Lck and Fyn protein tyrosine kinases in T lymphocyte plasma membranes. Mol Biol Cell 1999 10 : 891 905.
29. Gombos I, Kiss E, Detre C, Laszlo G, Matko J. Cholesterol and sphingolipids as lipid organizers of the immune cells' plasma membrane: their impact on the functions of MHC molecules, effector T-lymphocytes and T-cell death. Immunol Lett 2006 104 : 59 69.
30. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S, Tarakhovsky A, Okada M. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 2008 30 : 426 436.
31. Mayor J, Rao M. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 2004 5 : 231 240.
32. Brdicková N, Brdicka T, Andera L, Spicka J, Angelisová P, Milgram SL, Horejsí V. Interaction between two adaptor proteins, PAG and EBP50: a possible link between membrane rafts and actin cytoskeleton. FEBS Lett 2001 507 : 133 136.
33. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007 131 : 1190 1203.
34. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008 455 : 971 974.
35. Garber K. ALK, lung cancer and personalized therapy; portent of the future? J Natl Cancer Inst 2010 102 : 672 675.